Century Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 136.67 million compared to USD 130.93 million a year ago. Basic loss per share from continuing operations was USD 2.3 compared to USD 2.27 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.88 USD | -8.57% | -6.80% | -13.25% |
Apr. 12 | Piper Sandler Adjusts Price Target on Century Therapeutics to $9 From $10, Maintains Overweight Rating | MT |
Apr. 11 | Syncona agrees to sell stake in investee company for GBP7.4 million | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.25% | 237M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IPSC Stock
- News Century Therapeutics, Inc.
- Century Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023